Abstracts by key term: Innovations
Postpartum hemorrhage (PPH), defined as blood loss ≥500 ml within 24 hours of birth, is one of the most common causes of maternal mortality worldwide. In Germany, PPH occurred in 7.8% of the 693,000 births in 2023. In addition to medical therapy and uterine (balloon) tamponade, a vacuum-induced uterine compression (VUC) procedure has been available since 2024, enabling rapid hemostasis. Innovations such as VUC and the associated costs are initially not reflected in the DRG flat-rate fees in the inpatient sector, which is why additional fees are necessary for refinancing. At the same time, the product costs can be offset by resource-saving effects (including shorter lengths of stay, reduction in surgical procedures). To demonstrate these effects and evaluate them in monetary terms, a model was conducted: A resource saving in the DRG system leads to a downgrade of the DRG. Thus, a one-level reduction in the most common DRG results in a cost reduction of €983.24. The recent establishment of a specific procedure code for VUT will enable real-world analyses based on billing data in the future, as well as the long-term adjustment of case rates.
04.08.2025
„Innovationen unter Druck: Haben Spitzenforschung & Spitzenmedizin eine Zukunft?“ Unter diesen Titel stellte das forschende Pharmaunternehmen Roche sein diesjähriges Pressedinner anlässlich des Hauptstadtkongresses 2024 – erneut im österreichischen Restaurant Ottersbach zu Berlin mit den wohl besten Kalbsschnitzeln westlich Wiens. Diesmal referierten Prof. Wolfgang Schütte, Ärztlicher Direktor, Klinik für Innere Medizin II – Pneumologie am Krankenhaus Martha-Maria Halle-Dölau, der sich das Thema „Klinische Forschung: Verliert Deutschland den Anschluss?“ vornahm, und Friedrich Fichtner, Access Lead Strategic Pricing & Reimbursement der Roche Pharma AG, der in seinem Vortrag ausführte, warum ein AMNOG 2.0 benötigt wird. Fichtners Vortrag steht im Fokus dieser Berichterstattung.
03.08.2024
Medicines are among the most effective therapeutic measures used in the German healthcare system. However, the therapeutic progress that has been achieved in this area is also associated with considerable costs. The challenge for the healthcare system is to allow all patients to participate in this effective measure and in the progress that has been achieved, despite limited financial resources. The pharmaceutical expenditure of the statutory health insurance (GKV) has been rising continuously for years. This increase is only interrupted by legal regulations such as a price moratorium or manufacturer discounts, which usually have a short-term but not lasting effect and are also usually compensated by above-average increases in expenditure after the measures have expired. An expert report commissioned by TK by Prof. Stargard, University of Hamburg, Chair of Health Care Management shows that the end of the price moratorium and the reduction of the manufacturer discount, which has meanwhile increased, will result in additional expenditure of up to 1.4 billion euros for the health insurance companies would have drawn. The increase in drug spending is mainly caused by new drugs.
24.01.2013
Health care research and health care reality are closely intertwined. A constituent part of health services research is to analyze, evaluate and contribute to optimization of the reality of care. This is particularly important in the context of statutory health insurance. The implementation and optimization of care models is one of the core tasks of a health insurance company. Scientific evidence and health care management thus form a quasi-natural unit. The implementation of the findings from health services research into everyday care provides a direct benefit for those insured by the health insurance company as well as for the statutory health insurance.